Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BE
Eisai And Arena Pharmaceuticals Announce Publication Of Pooled Phase 3 Clinical Trial Analysis Of BELVIQ (lorcaserin HCl) CIV In Postgraduate Medicine
3 Biotech Stocks Near 52-Week Lows Worth Buying
These may be cheap biotech stocks, but they may not be cheap for long according to the three analysts we asked.
The 1 Biotech Stock I'm Definitely Not Buying
Three of our analysts chime in on which biotech stocks they think are the most risky.
Why Is Sanofi Betting on MannKind Corporation's Afrezza?
Sanofi's global dominance over the lucrative diabetes market is facing a serious challenge with the patent expiration of Lantus, the most commonly prescribed insulin in the world. Can MannKind's inhaled insulin product help Sanofi retain its edge?